Peptidify
Editorial standards
How we grade, what each dimension means, and which mistakes we consciously avoid.
Four dimensions. Never blended into one score.
A high-interest compound can have weak evidence. An approved drug can be boring. We keep the signals separate so you can think clearly.
Approved drugClinical trialsResearch chemicalPreclinicalDiscontinuedRegulatory status
Strong evidenceModerate evidenceLimited evidencePreclinical evidenceEvidence context
peptidanalogfragmentMolecular type
High interestMedium interestLow interestPublic interest
Official vs community — always separated
Regulator-approved labeling and trial designs never share a lane with self-reports.
Regulator-approved labeling and published study designs — never a recommendation.
Last-verified dates on every entry
A verification stamp on every entry shows exactly when its claims were last checked.
Systematic references are being expanded; verify sources directly before any decision.
191 monographs
- 79 approved drugs
- 22 in clinical trials
- 16 discontinued
- 32 preclinical evidence
Peptidify is an independent educational and research resource. It does not provide medical advice or sell peptides. Products labeled "research use only" are not intended for human use.